The table lists nausea of any grade at 25 to 48 percent in the SUSTAIN trials for semaglutide and 25 to 50 percent in the SURMOUNT trials for tirzepatide, calling both dose-dependent and typically resolving within four to eight weeks
Most health plans continue to cover GLP-1 medications for FDA-approved conditions such as diabetes and certain cardiovascular indications, while coverage for weight loss remains optional and highly variable
With aging, stress, and a fast-paced lifestyle, many people experience mood swings, anxiety, insomnia, memory decline, and brain fog from blood sugar fluctuations, inflammation, low energy, and nervous system overload
Labeled for: beef and dairy cattle, horses, sheep, swine, dogs and cats For intramuscular or subcutaneous injection
The most effective FDA-approved options for weight loss are tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic)